Large-scale progenitor cell expansion for multiple donors in a monitored hollow fibre bioreactor

Cytotherapy

Volumn 18, Issue 9, 2016, Pages 1219-1233

  Lambrechts, Toon ^a   Papantoniou, Ioannis ^a   Rice, Brent ^b   Schrooten, Jan ^a   Luyten, Frank P ^a   Aerts, Jean Marie ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Terumo BCT Inc   (United States)

Author keywords

bioreactor; mesenchymal stromal cell expansion; osteogenesis; process monitoring and control; process reproducibility; quality control

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE DEVELOPMENT; CELL ASSAY; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; CULTURE VESSEL; FEMALE; HOLLOW FIBER REACTOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; PERIOSTEUM; PRIORITY JOURNAL; PROCESS MONITORING; QUALITY CONTROL; STEM CELL EXPANSION; YOUNG ADULT; ANIMAL; BIOLOGICAL THERAPY; BIOREACTOR; BONE; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; CYTOLOGY; DEVICES; NUDE MOUSE; PROCEDURES; STEM CELL;

ADULT; ANIMALS; BIOREACTORS; BONE AND BONES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; FEMALE; HUMANS; MALE; MICE, NUDE; MIDDLE AGED; PERIOSTEUM; STEM CELLS; YOUNG ADULT;

EID: 84990240035     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.05.013     Document Type: Article

References (51)

1. [1] Culme-Seymour, E.J., Davie, N.L., Brindley, D.A., Edwards-Parton, S., Mason, C., A decade of cell therapy clinical trials (2000–2010). Regen Med 7 (2012), 455–462, 10.2217/rme.12.45.
2. [2] Heathman, T.R., Nienow, W., McCall, M.J., Coopman, K., Kara, B., Hewitt, C.J., The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med 10 (2015), 49–64.
3. [3] Curran, K.J., Brentjens, R.J., Sloan, M., Cancer, K., York, N., Chimeric antigen receptor t cells for cancer immunotherapy. J Clin Oncol, 2015, 10.1200/JCO.2014.60.3449.
4. [4] Maus, M.V., Grupp, S.A., Porter, D.L., June, C.H., Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123 (2014), 2625–2635, 10.1182/blood-2013-11-492231.organs.
5. [5] Bartunek, J., Behfar, A., Dolatabadi, D., Vanderheyden, M., Ostojic, M., Dens, J., et al. Cardiopoietic stem cell therapy in heart failure. J Am Coll Cardiol 61 (2013), 2329–2338, 10.1016/j.jacc.2013.02.071.
6. [6] Galipeau, J., The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 15 (2013), 2–8, 10.1016/j.jcyt.2012.10.002.
7. [7] Hourd, P., Ginty, P., Chandra, A., Williams, D.J., Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy 16 (2014), 1033–1047, 10.1016/j.jcyt.2014.03.005.
8. [8] Kaiser, A.D., Assenmacher, M., Schröder, B., Meyer, M., Orentas, R., Bethke, U., et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther 22 (2015), 72–78, 10.1038/cgt.2014.78.
9. [9] Jung, S., Panchalingam, K.M., Wuerth, R.D., Rosenberg, L., Behie, L.A., Large-scale production of human mesenchymal stem cells for clinical applications. Biotechnol Appl Biochem 59 (2012), 106–120, 10.1002/bab.1006.
10. [10] Simaria, A.S., Hassan, S., Varadaraju, H., Rowley, J., Warren, K., Vanek, P., et al. Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol Bioeng 111 (2014), 69–83, 10.1002/bit.25008.
11. [11] Beitzel, K., McCarthy, M.B.R., Cote, M.P., Durant, T.J.S., Chowaniec, D.M., Solovyova, O., et al. Comparison of mesenchymal stem cells (Osteoprogenitors) harvested from proximal humerus and distal femur during arthroscopic surgery. Arthroscopy 29 (2013), 301–308, 10.1016/j.arthro.2012.08.021.
12. [12] Fennema, E.M., Renard, A.J.S., Leusink, A., van Blitterswijk, C.A., de Boer, J., The effect of bone marrow aspiration strategy on the yield and quality of human mesenchymal stem cells. Acta Orthop 80 (2009), 618–621, 10.3109/17453670903278241.
13. [13] Sharma, S., Raju, R., Sui, S., Hu, W.-S., Stem cell culture engineering—process scale up and beyond. Biotechnol J 6 (2011), 1317–1329, 10.1002/biot.201000435.
14. [14] Rowley, J., Abraham, E., Campbell, A., Brandwein, H., Oh, S., Meeting lot-size challenges of manufacturing adherent cells for therapy. Bioprocess Int 10 (2012), 16–22.
15. [15] Bovy, T., Fairbank, A., Farid, S.S., Designing the most cost-effective manufacturing strategy for allogeneic cell-based strategies. Bioprocess Int 13 (2015), 36–43.
16. [16] Hanley, P.J., Mei, Z., Durett, A.G., da Graca Cabreira-Harrison, M., Klis, M., Li, W., et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy, 16, 2014, 1449, 10.1016/j.jcyt.2014.01.417.
17. [17] Siddappa, R., Licht, R., van Blitterswijk, C., Boer, J., de. Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res, 2007, 1029–1041, 10.1002/jor.
18. [18] Bara, J.J., Richards, R.G., Alini, M., Stoddart, M.J., Concise review: bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic. Stem Cells 32 (2014), 1713–1723, 10.1002/stem.1649.
19. [19] Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (2006), 315–317, 10.1080/14653240600855905.
20. [20] Oliveira, P., Silva, C., Cabral, J., Concise review: genomic instability in human stem cells: current status and future challenges. Stem Cells 32 (2014), 2824–2832.
21. [21] Eyckmans, J., Luyten, F.P., Species specificity of ectopic bone formation using periosteum-derived mesenchymal progenitor cells. Tissue Eng 12 (2006), 2203–2213.
22. [22] Eyckmans, J., Roberts, S.J., Schrooten, J., Luyten, F.P., A clinically relevant model of osteoinduction: a process requiring calcium phosphate and BMP/Wnt signalling. J Cell Mol Med 14 (2010), 1845–1856, 10.1111/j.1582-4934.2009.00807.x.
23. [23] Roberts, S.J., van Gastel, N., Carmeliet, G., Luyten, F.P., Uncovering the periosteum for skeletal regeneration: The stem cell that lies beneath. Bone 70 (2014), 10–18, 10.1016/j.bone.2014.08.007.
24. [24] De Bari, C., Dell'Accio, F., Luyten, F.P., Human periosteum–derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum 44 (2001), 85–95, 10.1002/1529-0131(200101)44:1<85:AID-ANR12>3.0.CO;2-6.
25. [25] De Bari, C., Dell'Accio, F., Vanlauwe, J., Eyckmans, J., Khan, I.M., Archer, C.W., et al. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum 54 (2006), 1209–1221, 10.1002/art.21753.
26. [26] Lambrechts, T., Papantoniou, I., Viazzi, S., Bovy, T., Schrooten, J., Luyten, F.P., et al. Evaluation of a monitored multiplate bioreactor for large-scale expansion of human periosteum derived stem cells for bone tissue engineering applications. Biochem Eng J, 2015, 10.1016/j.bej.2015.07.015.
27. [27] Hulspas, R., Titration of fluorochrome-conjugated antibodies for labeling cell surface markers on live cells. Curr Protoc Cytom, 2010, 1–9, 10.1002/0471142956.cy0629s54.
28. [28] Herzenberg, L.A., Tung, J., Moore, W.A., Herzenberg, L.A., Parks, D.R., Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol 7 (2006), 681–685, 10.1038/ni0706-681.
29. [29] Martin, I., Mastrogiacomo, M., Fluorescence microscopy imaging of bone for automated histomorphometry. Tissue 8 (2002), 847–852.
30. [30] Roberts, S.J., Geris, L., Kerckhofs, G., Desmet, E., Schrooten, J., Luyten, F.P., The combined bone forming capacity of human periosteal derived cells and calcium phosphates. Biomaterials 32 (2011), 4393–4405.
31. [31] Ogura, N., Kawada, M., Chang, W., Zhang, Q., Lee, S., Kondoh, T., et al. Differentiation of the human mesenchymal stem cells derived from bone marrow and enhancement of cell attachment by fibronectin. J Oral Sci 46 (2004), 207–213, 10.2334/josnusd.46.207.
32. [32] Jones, M., Varella-Garcia, M., Skokan, M., Bryce, S., Schowinsky, J., Peters, R., et al. Genetic stability of bone marrow–derived human mesenchymal stromal cells in the Quantum System. Cytotherapy 15 (2013), 1323–1339, 10.1016/j.jcyt.2013.05.024.
33. [33] Rojewski, M.T., Fekete, N., Baila, S., Nguyen, K., Fürst, D., Antwiler, D., et al. GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system. Cell Transplant 22 (2013), 1981–2000, 10.3727/096368912X657990.
34. [34] Lechanteur, C., Baila, S., Janssens, M.E., Giet, O., Briquet, A., Baudoux, E., et al. Large-scale clinical expansion of mesenchymal stem cells in the GMP-Compliant, closed automated quantum® cell expansion system: comparison with expansion in traditional T-Flasks. J Stem Cell Res Ther 04 (2014), 1–11, 10.4172/2157-7633.1000222.
35. [35] Wang, Y., Zhao, L., Smas, C., Sul, H.S., Pref-1 interacts with fibronectin to inhibit adipocyte differentiation. Mol Cell Biol 30 (2010), 3480–3492, 10.1128/MCB.00057-10.
36. [36] Singh, P., Schwarzbauer, J.E., Fibronectin and stem cell differentiation—lessons from chondrogenesis. J Cell Sci 125 (2012), 3703–3712, 10.1242/jcs.095786.
37. [37] Martino, M., Mochizuki, M., Rothenfluh, D.A., Rempel, S.A., Hubbell, J.A., Barker, T.H., Biomaterials Controlling integrin specificity and stem cell differentiation in 2D and 3D environments through regulation of fibronectin domain stability. Biomaterials 30 (2009), 1089–1097, 10.1016/j.biomaterials.2008.10.047.
38. [38] Jing, D., Punreddy, S., Sunil, N., Aysola, M., Murrel, J., Niss, K., Characterization of human mesenchymal stem cells: Expansion in a 3-L, single-use, stirred-tank bioreactor. Bioprocess Int 11 (2013), 30–36.
39. [39] dos Santos, F., Campbell, A., Fernandes-Platzgummer, A., Andrade, P.Z., Gimble, J.M., Wen, Y., et al. A xenogeneic-free bioreactor system for the clinical-scale expansion of human mesenchymal stem/stromal cells. Biotechnol Bioeng 9999 (2014), 1–31, 10.1002/bit.25187.
40. [40] Chai, Y.C., Roberts, S.J., Desmet, E., Kerckhofs, G., van Gastel, N., Geris, L., et al. Mechanisms of ectopic bone formation by human osteoprogenitor cells on CaP biomaterial carriers. Biomaterials 33 (2012), 3127–3142, 10.1016/j.biomaterials.2012.01.015.
41. [41] Santoro, R., Olivares, A.L., Brans, G., Wirz, D., Longinotti, C., Lacroix, D., et al. Bioreactor based engineering of large-scale human cartilage grafts for joint resurfacing. Biomaterials 31 (2010), 8946–8952, 10.1016/j.biomaterials.2010.08.009.
42. [42] Trainor, N., Pietak, A., Smith, T., Rethinking clinical delivery of adult stem cell therapies. Nat Biotechnol 32 (2014), 729–735, 10.1038/nbt.2970.
43. [43] Liu, Y., Hourd, P., Chandra, A., Williams, D.J., Human cell culture process capability: a comparison of manual and automated production. J Tissue Eng Regen Med 4 (2010), 45–57, 10.1002/term.
44. [44] Archibald, P.R.T., Chandra, A., Thomas, D., Morley, G., Lekishvili, T., Devonshire, A., et al. Comparability of scalable, automated hMSC culture using manual and automated process steps. Biochem Eng J, 2015, 1–15, 10.1016/j.bej.2015.07.001.
45. [45] Terstegge, S., Laufenberg, I., Pochert, J., Schenk, S., Itskovitz-Eldor, J., Endl, E., et al. Automated maintenance of embryonic stem cell cultures. Biotechnol Bioeng 96 (2007), 1199–1210.
46. [46] Paull, D., Sevilla, A., Zhou, H., Hahn, A.K., Kim, H., Napolitano, C., et al. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods 12 (2015), 885–892, 10.1038/nmeth.3507.
47. [47] Foley, L., Whitaker, M., Concise review: cell therapies: the route to widespread adoption. Stem Cells Transl Med 1 (2012), 438–447, 10.5966/sctm.2011-0009.
48. [48] Heathman, T.R.J., Rafiq, Q.A., Chan, A.K.C., Coopman, K., Nienow, A.W., Kara, B., et al. Characterisation of human mesenchymal stem cells from multiple donors and the implications for large scale bioprocess development. Biochem Eng J, 2015, 10.1016/j.bej.2015.06.018.
49. [49] EMA, Guideline on process validation for finished products - information and data to be provided in regulatory submissions. 2014 1–15.
50. [50] FDA, Guidance for Industry Process Validation: General Principles and Practices. 2011, 22.
51. [51] Lambrechts, T., Papantoniou, I., Sonnaert, M., Schrooten, J., Aerts, J.-M., Model-based cell number quantification using online single-oxygen sensor data for tissue engineering perfusion bioreactors. Biotechnol Bioeng 111 (2014), 1982–1992, 10.1002/bit.25274.